Aviva shares are up 42% in 2025 – can they repeat it in 2026 and boost your ISA?

Aviva shares jumped in 2025 – I’m tracking them in my ISA to see if dividends and growth can keep building my passive income next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together

Image source: Getty Images

After years in the doldrums, the Aviva (LSE: AV.) share price has come alive in 2025, making it one of the best-performing stocks in the FTSE 100. With the Direct Line integration progressing at pace and a continued shift toward a capital-light model, the key question is whether this momentum can carry into 2026.

Diversified business model

One aspect many investors miss is that Aviva is both a life and non-life insurer. That distinction matters when judging performance over time.

Life insurance is long term and investment-heavy, while non-life insurance is short term and underwriting-driven. Blending the two makes headline profits harder to interpret.

That’s why I focus on a single metric that cuts through the noise: group adjusted operating profit (GAOP). It doesn’t appear directly on the balance sheet or income statement.

GAOP strips out swings in bond yields and equity markets that can distort asset values. Instead, it assumes steady long-term returns, allowing investors to see how well Aviva’s core business is actually performing, rather than how favourable markets happened to be in any given year.

Rising profits

The chart below shows GAOP rising sharply over the past few years, and highlights which divisions contribute the largest share to the total.

Chart showing Aviva's profits broken down by Division

Chart generated by author

The key to judging whether GAOP will keep rising is the contractual service margin (CSM).

Under accounting rules, insurers split the value of a policy into two parts:

  1. Expected future cash flows – premiums in, claims and expenses out
  2. The CSM – essentially unearned profit, recognised gradually as the insurer provides coverage

Think of the CSM as a profit reservoir: Aviva can’t book all the profit when a policy is sold. Instead, it releases it steadily over the life of the policy as the service is delivered.

The impact of the CSM on GAOP is clear. In 2023, CSM stood at £1,170m, rising to £1,852m in 2024. This growth shows the company has a larger reservoir of unearned profits to release in the coming years, providing a strong boost to GAOP and underlying earnings.

Risks

One risk for Aviva’s Direct Line purchase is the broader softening in UK insurance premiums.

Recent industry data shows quoted motor and home insurance premiums have continued to trend lower year on year. Average motor premiums are down around 16% compared with early 2025 levels, with declines across other personal lines as competition intensifies.

If falling premiums continue into 2026, Direct Line’s motor and home insurance profits could be squeezed, limiting the contribution Aviva expects from the acquisition. High competition and ongoing claims costs may mean the company has to lower its prices further or struggle to raise them, which could weigh on future earnings.

Bottom line

For me, Aviva remains a core holding in my Stocks and Shares ISA for passive income. The company’s 5.3% dividend yield, supported by GAOP dividend cover of 1.92 times, provides a reliable income stream that compounds tax-free over time.

GAOP growth, a rising CSM, and disciplined capital-light execution all point to sustainable long-term earnings. I’ve recently added to my holding, reflecting my confidence in how the business is performing.

Combined with the diversified mix of life and non-life insurance, I expect the business to continue generating steady dividends, while capital growth in the stock could further boost my ISA over time.

Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Readers are responsible for carrying out their own due diligence and for obtaining professional advice before making any investment decisions.

Andrew Mackie has positions in Aviva Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

Here’s how investors can aim for £11,363 a year in passive income from £20,000 in this overlooked FTSE media gem

I think this media stock is commonly overlooked by investors looking for high passive income, but it shouldn’t be, given…

Read more »

Tesla car at super charger station
Investing Articles

Why is Tesla stock down 30% since late 2025?

Tesla stock has been a bit of a car crash in 2026. Edward Sheldon looks at what’s going on, and…

Read more »

UK supporters with flag
Investing Articles

Is Wise now the UK stock market’s top growth share?

Wise rose around 4% in the UK stock market yesterday, bringing its four-year gain to 135%. Why are investors warming…

Read more »

Warhammer World gathering
Investing Articles

£20,000 invested in this FTSE 100 stock 10 years ago is now worth this astonishing amount…

This FTSE 100 stock's delivered an amazing return over the past 10 years. James Beard considers whether it’s worth holding…

Read more »